Erdogan-Trinkaus Ipek
Chief Commercial Officer
Erdogan-Trinkaus Ipek has filed 2 SEC Form 4 filings (4 transaction rows) across 1 company, with disclosures dating back to 2025. 2 of those filings fall inside the rolling window. Most recent filing: Nov 12, 2026.
On the most recent filing, Erdogan-Trinkaus Ipek is listed as Chief Commercial Officer at Eton Pharmaceuticals, Inc. Inside the rolling window, Erdogan-Trinkaus Ipek reported no open-market purchases and 1 open-market sale totaling $236K in ETON.
Companies traded
Other insiders at ETON
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$236K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Erdogan-Trinkaus Ipek made?
Erdogan-Trinkaus Ipek has filed 2 SEC Form 4 filings (4 transaction rows) across 1 company since 2025.
Which companies does Erdogan-Trinkaus Ipek trade?
Erdogan-Trinkaus Ipek has filed SEC Form 4 disclosures for 1 company, including ETON.
When was Erdogan-Trinkaus Ipek's most recent SEC Form 4 filing?
Erdogan-Trinkaus Ipek's most recent SEC Form 4 filing on Tracefour is dated Nov 12, 2026.
What is Erdogan-Trinkaus Ipek's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Erdogan-Trinkaus Ipek is listed as Chief Commercial Officer.
What is Erdogan-Trinkaus Ipek's total buy and sell value in the current window?
Inside the rolling retention window, Erdogan-Trinkaus Ipek bought $0 and sold $236K based on SEC Form 4 filings.
What was Erdogan-Trinkaus Ipek's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 3,500 ETON shares on 2026-11-10, worth $236K, per SEC Form 4 filings.